Stay updated with breaking news from Primary Biliary. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Iqirvo® (elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver
Interim results from the open-label, phase 3 study show seladelpar demonstrated clinically meaningful improvements in markers of cholestasis and liver injury.
The PDUFA date refers to the deadline set by the US Food and Drug Administration for reviewing drug applications.
Dublin, April 26, 2024 (GLOBE NEWSWIRE) -- The
Cash and cash equivalents totaled €77.8 million as of December 31, 2023Revenues amounted to €28.6 million as of December 31, 2023 including a milestone payment of €13.3 millionTopline interim...